PFA
FBRX icon

Pure Financial Advisors’s Forte Biosciences FBRX Stock Holding History

Pure Financial Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-210
Closed -$648K – 141
2018
Q4 		$648K Hold
210
– – 0.13% 76
2018
Q3 		$1.23M Buy
+210
New +$799K 0.27% 52

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pure Financial Advisors's FBRX Position: Q1 2019 in Review

Pure Financial Advisors sold out of Forte Biosciences (FBRX) in Q1 2019, closing a stake of 210 shares — an estimated $648K sold.

Pure Financial Advisors first reported a position in FBRX in Q3 2018 and held it in 2 quarters. The position peaked at $1.23M in Q3 2018. 78 funds tracked by Wall St. Rank hold FBRX as of Q1 2019.

  • Pure Financial Advisors reported no remaining Forte Biosciences position as of Q1 2019 after selling out during the quarter.
  • Pure Financial Advisors sold 210 Forte Biosciences shares in Q1 2019, an estimated $648K.
  • Pure Financial Advisors first reported a position in Forte Biosciences in Q3 2018 and held it in 2 quarters.
  • Pure Financial Advisors's Forte Biosciences position peaked at $1.23M in Q3 2018.
  • 78 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2019.

Based on Pure Financial Advisors's 13F filing for Q1 2019, filed 5 Apr 2019.